Bank of America
EPRX

Bank of America’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Bank of America’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.94M Buy
268,221
+14,900
+6% +$120K ﹤0.01% 4135
2025
Q4 		$1.91M Buy
253,321
+207,744
+456% +$1.28M ﹤0.01% 4101
2025
Q3 		$269K Buy
45,577
+33,018
+263% +$180K ﹤0.01% 6135
2025
Q2 		$72.3K Buy
12,559
+10,059
+402% +$38.6K ﹤0.01% 6662
2025
Q1 		$8.2K Buy
+2,500
New +$8.63K ﹤0.01% 7148

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $14.8B AUM 15.12% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Bank of America's EPRX Position: Q1 2026 in Review

Bank of America increased its Eupraxia Pharmaceuticals (EPRX) stake by 5.9% in Q1 2026, buying an estimated $120K and bringing the position to 268,221 shares worth $1.94M. The position accounts for ﹤0.01% of the portfolio, ranked #4135.

Bank of America first reported a position in EPRX in Q1 2025 and has held it in 5 quarters since. 54 funds tracked by Wall St. Rank hold EPRX as of Q1 2026.

  • Bank of America held 268,221 shares of Eupraxia Pharmaceuticals worth $1.94M as of Q1 2026.
  • Bank of America bought 14,900 Eupraxia Pharmaceuticals shares in Q1 2026, an estimated $120K.
  • Eupraxia Pharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #4135 holding.
  • Bank of America first reported a position in Eupraxia Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • 54 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.